CRISPR-Edited Stem Cells in a Patient with HIV and Acute Lymphocytic Leukemia

Key Points

Key points are not available for this paper at this time.

Abstract

disruption in lymphocytes was only approximately 5%, which indicates the need for further research into this approach. (Funded by the Beijing Municipal Science and Technology Commission and others; ClinicalTrials.gov number, NCT03164135.).

CRISPR-Edited Stem Cells in a Patient with HIV and Acute Lymphocytic Leukemia

Key Points

Abstract

Cite This Study